MAGEL2 and fatty liver disease: Besides affecting body weight and food intake, JD5037 was found to be as efficacious as SLV319 in normalizing the elevated blood glucose and serum insulin levels, improving glucose tolerance and insulin resistance, reversing the HFD-induced hepatic steatosis, and improving the plasma lipid profile of obese Magel2-null mice.